Genprex

Tagged: Diabetes

Genprex to Present at the 2024 BIO International Convention

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024.

Read More

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read More

Genprex to Present at Upcoming BIO CEO & Investor Conference

Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.

Read More

Genprex Provides Business Update and Outlook for 2024 

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024

Poised for FDA guidance regarding diabetes gene therapy program in 2024

Read More

Genprex to Present at BIO-Europe 2023 Conference 

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC

Read More

In Search Of A Cure: The Growing Number Of Diabetics Is Inspiring A New Generation Of Therapies

Diabetes is the most expensive chronic illness in the U.S., with $1 of every $4 in healthcare costs going to care for diabetics. The National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) estimates that $237 billion is spent directly on diabetes-related medical costs every year, while another $90 billion is lost each year due to reduced productivity associated with diabetes.

Read More

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer

Read More

Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex announced the closing of its previously announced registered direct offering to healthcare-focused institutional investors of 7,425,744 shares of the Company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant.  The offering was priced at-the-market under the Nasdaq rules. 

Read More